PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Qiyun ShiJuncheng XuhongTao LuoJia GeFeng LiuYang LanQingqiu ChenPeng TangLinjun FanLi ChenYan LiangMinghao WangYing HuYi ZhangXiu-Wu BianXiaowei QiJun JiangPublished in: British journal of cancer (2022)
Our data suggest that HER2-positive breast cancers with activating mutations in PIK3CA are less likely to benefit from pyrotinib combined with trastuzumab neoadjuvant therapy.
Keyphrases
- locally advanced
- positive breast cancer
- rectal cancer
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- squamous cell carcinoma
- radiation therapy
- metastatic breast cancer
- lymph node
- signaling pathway
- protein kinase
- electronic health record
- big data
- tyrosine kinase
- mesenchymal stem cells
- bone marrow
- machine learning
- young adults
- cell therapy
- data analysis
- artificial intelligence